AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...

Alvotech has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea. See why ALVO stock is a Strong Buy.

MoneyShow presents top investment ideas for 2026 from leading advisors. Part 1 includes AbbVie, Alexandria Real Estate Equities, Arbor Realty, Archer Aviation, Ares Management & Aris Mining.

Income investors can rely on these stocks.

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

CVS Health outlined its efforts to decrease prior authorizations, reduce hospital readmissions and emergency room visits and ...

AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

Let's consider three of them: Eli Lilly ( LLY +0.52%), AbbVie ( ABBV 0.31%), and Intuitive Surgical ( ISRG 1.15%). Here's why ...

As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade ...

Though far from the first large drugmaker to strike a pricing deal with the Trump administration, AbbVie’s new accord is ...